Quadrant Capital Group LLC Sage Therapeutics, Inc. Transaction History
Quadrant Capital Group LLC
- $1.43 Billion
- Q4 2024
A detailed history of Quadrant Capital Group LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Quadrant Capital Group LLC holds 2,019 shares of SAGE stock, worth $14,678. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,019
Previous 1,120
80.27%
Holding current value
$14,678
Previous $8,000
25.0%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding SAGE
# of Institutions
194Shares Held
45MCall Options Held
304KPut Options Held
117K-
Black Rock Inc. New York, NY5.22MShares$37.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.84MShares$35.2 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.59MShares$33.4 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.46MShares$32.4 Million0.48% of portfolio
-
Rtw Investments, LP New York, NY3MShares$21.8 Million0.27% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $432M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...